Skip to main content

12-10-2016 | Osteoarthritis | Review | Article

Emerging Targets for the Management of Osteoarthritis Pain

Current Osteoporosis Reports

Authors: Anne-Marie Malfait, Richard J. Miller

Publisher: Springer US


Worldwide, osteoarthritis (OA) is one of the leading causes of chronic pain, for which adequate relief is not available. Ongoing peripheral input from the affected joint is a major factor in OA-associated pain. Therefore, this review focuses predominantly on peripheral targets emerging in the preclinical and clinical arena. Nerve growth factor is the most advanced of these targets, and its blockade has shown tremendous promise in clinical trials in knee OA. A number of different types of ion channels, including voltage-gated sodium channels and calcium channels, transient receptor potential channels, and acid-sensing ion channels, are important for neuronal excitability and play a role in pain genesis. Few channel blockers have been tested in preclinical models of OA, with varying results. Finally, we discuss some examples of G-protein coupled receptors, which may offer attractive therapeutic strategies for OA pain, including receptors for bradykinin, calcitonin gene-related peptide, and chemokines. Since many of the pathways described above can be selectively and potently targeted, they offer an exciting opportunity for pain management in OA, either systemically or locally.

Please log in to get access to this content

Related topics

EULAR 2020 E-Congress hub

Access the latest news and expert video commentary from the EULAR 2020 E-Congress.

Image Credits